Cat. No.: HY-151978

ZC0109

Avis client

Based on 1 Customer Validation

ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 (TrxR1) with IC₅₀s of 50 nM and 3.0 μM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads to cancer cells apoptosis.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.86%
CAS No.: 3037850-79-3
Formule: C₂₂H₂₀BrFN₈O₄S
Masse moléculaire:591.41

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

ZC0109 Chemical Structure

CAS No.: 3037850-79-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvant et solubilité
- In Vitro
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

IC50: 50 nM (IDO1), 3.0 μM (TrxR1)^[1]

Voir tous les produits spécifiques à Isoform Indoleamine 2,3-Dioxygenase (IDO) :

Cellular Effect

Cell Line	Type	Value	Description	References
CT26	IC₅₀	12.4 μM Compound: 12d; ZC0109	Cytotoxicity against mouse CT26 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against mouse CT26 cells incubated for 48 hrs by CCK-8 assay	[PMID: 36370550]
HCT-116	IC₅₀	1.52 μM Compound: 12d; ZC0109	Cytotoxicity against TrxR1 knockdown human HCT-116 cells incubated for 24 hrs by CCK-8 assay (Rvb = 3.08 +/- 0.55 uM) Cytotoxicity against TrxR1 knockdown human HCT-116 cells incubated for 24 hrs by CCK-8 assay (Rvb = 3.08 +/- 0.55 uM)	[PMID: 36370550]
HCT-116	IC₅₀	1.67 nM Compound: 12d; ZC0109	Cytotoxicity against human HCT-116 cells transfected with TrxR1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 3.49 +/- 0.28 uM) Cytotoxicity against human HCT-116 cells transfected with TrxR1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 3.49 +/- 0.28 uM)	[PMID: 36370550]
HCT-116	IC₅₀	18.08 nM Compound: 12d; ZC0109	Cytotoxicity against IDO1 knockdown human HCT-116 cells incubated for 24 hrs by CCK-8 assay (Rvb = 36.50 +/- 3.20 nM) Cytotoxicity against IDO1 knockdown human HCT-116 cells incubated for 24 hrs by CCK-8 assay (Rvb = 36.50 +/- 3.20 nM)	[PMID: 36370550]
HCT-116	IC₅₀	3.33 μM Compound: 12d; ZC0109	Cytotoxicity against human HCT-116 cells incubated for 24 hrs CCK-8 assay Cytotoxicity against human HCT-116 cells incubated for 24 hrs CCK-8 assay	[PMID: 36370550]
HCT-116	IC₅₀	3.44 μM Compound: 12d; ZC0109	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by CCK-8 assay	[PMID: 36370550]
HCT-116	IC₅₀	3.44 μM Compound: 12d; ZC0109	Cytotoxicity against human HCT-116 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HCT-116 cells incubated for 48 hrs by CCK-8 assay	[PMID: 36370550]
HCT-116	IC₅₀	3.79 μM Compound: 12d; ZC0109	Cytotoxicity against human HCT-116 cells transfected with IDO1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 3.49 +/- 0.28 uM) Cytotoxicity against human HCT-116 cells transfected with IDO1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 3.49 +/- 0.28 uM)	[PMID: 36370550]
HCT-116	IC₅₀	60.83 μM Compound: 12d; ZC0109	Cytotoxicity against human HCT-116 cells incubated for 24 hrs in presence of NAC CCK-8 assay Cytotoxicity against human HCT-116 cells incubated for 24 hrs in presence of NAC CCK-8 assay	[PMID: 36370550]
HeLa	IC₅₀	10.09 μM Compound: 12d; ZC0109	Cytotoxicity against human HeLa cells transfected with IDO1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 9.74 +/- 1.64 uM) Cytotoxicity against human HeLa cells transfected with IDO1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 9.74 +/- 1.64 uM)	[PMID: 36370550]
HeLa	IC₅₀	10.2 μM Compound: 12d; ZC0109	Cytotoxicity against human HeLa cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HeLa cells incubated for 48 hrs by CCK-8 assay	[PMID: 36370550]
HeLa	IC₅₀	16.08 μM Compound: 12d; ZC0109	Cytotoxicity against human HeLa cells incubated for 24 hrs CCK-8 assay Cytotoxicity against human HeLa cells incubated for 24 hrs CCK-8 assay	[PMID: 36370550]
HeLa	IC₅₀	26.13 μM Compound: 12d; ZC0109	Cytotoxicity against IDO1 knockdown human HeLa cells incubated for 24 hrs by CCK-8 assay (Rvb = 45.93 +/- 2.23 nM) Cytotoxicity against IDO1 knockdown human HeLa cells incubated for 24 hrs by CCK-8 assay (Rvb = 45.93 +/- 2.23 nM)	[PMID: 36370550]
HeLa	IC₅₀	4.86 μM Compound: 12d; ZC0109	Cytotoxicity against human HeLa cells transfected with TrxR1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 9.74 +/- 1.64 uM) Cytotoxicity against human HeLa cells transfected with TrxR1 siRNA incubated for 24 hrs by CCK-8 assay (Rvb = 9.74 +/- 1.64 uM)	[PMID: 36370550]
HeLa	IC₅₀	7.2 μM Compound: 12d; ZC0109	Cytotoxicity against TrxR1 knockdown human HeLa cells incubated for 24 hrs by CCK-8 assay (Rvb = 13.79 +/- 2 uM) Cytotoxicity against TrxR1 knockdown human HeLa cells incubated for 24 hrs by CCK-8 assay (Rvb = 13.79 +/- 2 uM)	[PMID: 36370550]
HeLa	IC₅₀	74.15 μM Compound: 12d; ZC0109	Cytotoxicity against human HeLa cells incubated for 24 hrs in presence of NAC CCK-8 assay Cytotoxicity against human HeLa cells incubated for 24 hrs in presence of NAC CCK-8 assay	[PMID: 36370550]

In Vitro

ZC0109 (24 h) inhibits cancer cells with IC₅₀s of 3.44 μM (HCT-116), 12.4 μM (CT26), and 10.2 μM (HeLa), respectively^[1].
ZC0109 (2.5-10 μM; 24 h) induces ROS accumulation in HCT-116 and HeLa cells^[1].
ZC0109 (2.5-10 μM; 24 h) induces apoptosis and G1/S cell cycle arrest in cancer cell^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

HCT-116 cells and HeLa cells
Concentration:

2.5 μM, 5 μM, and 10 μM
Incubation Time:

24 hours
Result:

Arrested cell cycle at G1/S phase.

In Vivo

ZC0109 (15, 30, and 60 mg/kg; p.o.; once daily for 28 d) reduces Kyn/Trp metabolism in C57BL/6 mice^[1].
ZC0109 (60 mg/kg; p.o.; once daily for 28 d) decreases tumor growth and increases accumulation and infiltration of T cells in CT-26 cells transplanted immunocompetent BALB/c mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 3037850-79-3
Appearance Solid
Masse moléculaire 591.41
Formule C₂₂H₂₀BrFN₈O₄S
Color White to off-white
SMILES

O/N=C(C1=NON=C1NCCCC2=NN=C(S2)NC(CC3=CC=C(C=C3)O)=O)\NC4=CC(Br)=C(C=C4)F
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (84.54 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6909 mL

8.4544 mL

16.9087 mL

5 mM

0.3382 mL

1.6909 mL

3.3817 mL

10 mM

0.1691 mL

0.8454 mL

1.6909 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (274 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Zhou J, et al. Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114860. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6909 mL	8.4544 mL	16.9087 mL	42.2719 mL
	5 mM	0.3382 mL	1.6909 mL	3.3817 mL	8.4544 mL
	10 mM	0.1691 mL	0.8454 mL	1.6909 mL	4.2272 mL
	15 mM	0.1127 mL	0.5636 mL	1.1272 mL	2.8181 mL
	20 mM	0.0845 mL	0.4227 mL	0.8454 mL	2.1136 mL
	25 mM	0.0676 mL	0.3382 mL	0.6763 mL	1.6909 mL
	30 mM	0.0564 mL	0.2818 mL	0.5636 mL	1.4091 mL
	40 mM	0.0423 mL	0.2114 mL	0.4227 mL	1.0568 mL
	50 mM	0.0338 mL	0.1691 mL	0.3382 mL	0.8454 mL
	60 mM	0.0282 mL	0.1409 mL	0.2818 mL	0.7045 mL
	80 mM	0.0211 mL	0.1057 mL	0.2114 mL	0.5284 mL

Keywords

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

ZC0109

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Voir tous les produits spécifiques à Isoform Indoleamine 2,3-Dioxygenase (IDO)

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

ZC0109

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Voir tous les produits spécifiques à Isoform Indoleamine 2,3-Dioxygenase (IDO)

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

ZC0109 Related Classifications

HY-151978 Related Classifications